(Q39085019)

8 September 2017

title

Retargeting NK-92 for anti-melanoma activity by a TCR-like single-domain antibody (English)

1 reference

8 September 2017

1 reference

Ge Zhang

1

1 reference

8 September 2017

Rongzhi Liu

2

1 reference

8 September 2017

Xuekai Zhu

3

1 reference

8 September 2017

Lei Wang

4

1 reference

8 September 2017

Juan Ma

5

1 reference

8 September 2017

Huamin Han

6

1 reference

8 September 2017

Xiaomin Wang

7

1 reference

8 September 2017

Ganlin Zhang

8

1 reference

8 September 2017

Wen He

9

1 reference

8 September 2017

Wei Wang

10

1 reference

8 September 2017

Changzhen Liu

11

1 reference

8 September 2017

Shenghua Li

12

1 reference

8 September 2017

Meiyi Sun

13

1 reference

8 September 2017

Bin Gao

14

1 reference

8 September 2017

publication date

8 October 2013

1 reference

Immunology & Cell Biology

8 September 2017

published in

1 reference

8 September 2017

volume

91

1 reference

8 September 2017

issue

10

1 reference

8 September 2017

page(s)

615-624

1 reference

Immunotherapy of malignant melanoma in a SCID mouse model using the highly cytotoxic natural killer cell line NK-92.

8 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.45

Cellular Immunotherapy of Malignancies Using the Clonal Natural Killer Cell Line NK-92

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.45

Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.45

Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.45

NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.45

Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.45

Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.45

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.45

Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.45

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.45

Cancer regression in patients after transfer of genetically engineered lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.45

Antitumor activity of immunotoxins with T-cell receptor-like specificity against human melanoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.45

Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.45

Immune responses to the HLA-A*0201-restricted epitopes of tyrosinase and glycoprotein 100 enable control of melanoma outgrowth in HLA-A*0201-transgenic mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.45

Expanding the targets available to therapeutic antibodies via novel disease-specific markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.45

TCR-like biomolecules target peptide/MHC Class I complexes on the surface of infected and cancerous cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.45

T-cell-receptor-like antibodies - generation, function and applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.45

Identification of HLA-A2-restricted CTL epitopes of a novel tumour-associated antigen, KIF20A, overexpressed in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.45

An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.45

Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.45

Targeting the intracellular WT1 oncogene product with a therapeutic human antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.45

Engineering the first chimeric antibody in targeting intracellular PRL-3 oncoprotein for cancer therapy in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.45

Selective targeting of melanoma and APCs using a recombinant antibody with TCR-like specificity directed toward a melanoma differentiation antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.45

Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.45

Functional balance between T cell chimeric receptor density and tumor associated antigen density: CTL mediated cytolysis and lymphokine production

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.45

Engineering T cells for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.45

New views on natural killer cell-based immunotherapy for melanoma treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.45

Novel approaches using natural killer cells in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.45

Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.45

Lipopeptide-based melanoma cancer vaccine induced a strong MART-27-35-cytotoxic T lymphocyte response in a preclinal study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.45

Identification of single-domain, Bax-specific intrabodies that confer resistance to mammalian cells against oxidative-stress-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.45

Pentamerization of single-domain antibodies from phage libraries: a novel strategy for the rapid generation of high-avidity antibody reagents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.45

Pentamerisation of a scFv directed against TRAIL receptor 2 increases its antitumour efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.45

Cost efficient and effective gene transfer into the human natural killer cell line, NK92.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.45

COMBODY: one-domain antibody multimer with improved avidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.45

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/ICB.2013.45

1 reference

8 September 2017

1 reference